Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Breast Cancer Research and Treatment

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-016-4036-0PMID 27785654PMCID PMC5225037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The immune microenvironment of breast ductal carcinoma in situ

  2016cited by this paper
• Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score

  2015cited by this paper
• Treatment Selection for Patients with Ductal Carcinoma In Situ (DCIS) of the Breast Using the University of Southern California/Van Nuys (USC/VNPI) Prognostic Index

  2015cited by this paper
• Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer

  2015cited by this paper
• Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study

  2015cited by this paper
• Rethinking the Standard for Ductal Carcinoma In Situ Treatment.

  2015cited by this paper
• Role of inflammatory infiltrates in triple negative breast cancer

  2015cited by this paper
• Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis

  2015cited by this paper
• Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

  2015cited by this paper
• Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

  2015cited by this paper
• The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

  2014cited by this paper
• New Insights into the Role of the Immune Microenvironment in Breast Carcinoma

  2013cited by this paper
• The role of tumor-associated macrophages in breast cancer progression

  2013cited by this paper
• CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.

  2013cited by this paper
• FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast

  2013cited by this paper
• A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

  2013cited by this paper
• Ductal carcinoma in situ of the breast: current concepts and future directions.

  2013cited by this paper
• Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics

  2011cited by this paper
• Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software

  2011cited by this paper
• Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome

  2011cited by this paper
• Predictors of Local Recurrence in a Population-Based Cohort of Women with Ductal Carcinoma In Situ Treated with Breast Conserving Surgery Alone

  2011cited by this paper
• Absolute Risk Reductions for Local Recurrence after Postoperative Radiotherapy after Sector Resection for Ductal Carcinoma in Situ of the Breast

  2011cited by this paper
• Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ.

  2010cited by this paper
• Regulatory T cells and breast cancer: implications for immunopathogenesis

  2010cited by this paper
• Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ

  2010cited by this paper
• Predictors of Local Recurrence in a Population-Based Cohort of Women with Ductal Carcinoma In Situ Treated with Breast Conserving Surgery Alone

  2010cited by this paper
• Microinvasive Carcinoma of the Breast

  2008cited by this paper
• Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast.

  2008cited by this paper
• Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

  2007cited by this paper
• CellProfiler: image analysis software for identifying and quantifying cell phenotypes

  2006cited by this paper
• Magnetic resonance imaging captures the biology of ductal carcinoma in situ.

  2006cited by this paper
• Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

  2006cited by this paper
• The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.

  2003cited by this paper
• Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

  2003cited by this paper
• Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.

  2003cited by this paper
• Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

  2001cited by this paper
• Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.

  2001cited by this paper
• Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

  1998cited by this paper
• Angiogenesis and inflammation in ductal carcinoma in situ of the breast

  1997cited by this paper
• Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation.

  1992cited by this paper
• Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy

  1991cited by this paper
• Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis

  1990cited by this paper

• B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer

  2025cites this paper
• Evaluating the impact of using bone marrow-derived macrophages to turn early tumor sites into hot early tumor sites.

  2025cites this paper
• Exploring and validating genetic associations between immune cells and breast cancer

  2025cites this paper
• Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights

  2025influential citation
• DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges

  2025cites this paper
• Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS)

  2025cites this paper
• Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.

  2025cites this paper
• Expression of T cell-related proteins in breast ductal carcinoma in situ.

  2024cites this paper
• B cells enhance IL-1 beta driven invasiveness in triple-negative breast cancer

  2024cites this paper
• From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment

  2024cites this paper
• Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

  2024cites this paper
• Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study

  2024influential citation
• Association of the pathomics-collagen signature with lymph node metastasis in colorectal cancer: a retrospective multicenter study

  2024cites this paper
• Tumor microenvironmental determinants of high-risk DCIS progression

  2024cites this paper
• Tools to Guide Radiation Oncologists in the Management of DCIS

  2024cites this paper
• Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance

  2024cites this paper
• Everybody needs good neighbours: the progressive DCIS microenvironment.

  2023cites this paper
• Surformer: An interpretable pattern-perceptive survival transformer for cancer survival prediction from histopathology whole slide images

  2023cites this paper
• Isogenic Mammary Models of Intraductal Carcinoma Reveal Progression to Invasiveness in the Absence of a Non-Obligatory In Situ Stage

  2023cites this paper
• Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review

  2023influential citation
• Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast

  2022cites this paper
• The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ

  2022cites this paper
• Differences in tolerogenic status of NK cells between luminal A type, luminal B type, and triple-negative breast cancer.

  2022cites this paper
• Learning to distinguish progressive and non-progressive ductal carcinoma in situ

  2022cites this paper
• Hyperspectral three-dimensional absorption imaging using snapshot optical tomography.

  2022cites this paper
• Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ

  2022cites this paper
• Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

  2022cites this paper
• Immunologic determinants of mammary tumors: PD-L1 and TILS

  2022cites this paper
• Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk

  2022cites this paper
• Notch Signaling in Breast Tumor Microenvironment as Mediator of Drug Resistance

  2022cites this paper
• Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression

  2022cites this paper
• Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2

  2022influential citation
• Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ

  2022cites this paper
• Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.

  2022cites this paper
• Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment

  2021cites this paper
• Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence

  2021cites this paper
• Expression Profile Analysis Identifies a Novel Seven Immune-Related Gene Signature to Improve Prognosis Prediction of Glioblastoma

  2021cites this paper
• Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ

  2021cites this paper
• Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer

  2021influential citation
• Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast

  2021cites this paper
• Alteration of Macrophage Infiltrating Compartment: A Novel View on Oral Carcinogenesis

  2021cites this paper
• The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ

  2021cites this paper
• CD8+ T cells from experimental in situ breast carcinoma interfere with bone homeostasis.

  2021cites this paper
• Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection

  2021cites this paper
• Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines.

  2021cites this paper
• DCIS genomic signatures define biology and clinical outcome: Human Tumor Atlas Network (HTAN) analysis of TBCRC 038 and RAHBT cohorts

  2021cites this paper
• Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis

  2021cites this paper
• The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer

  2021cites this paper
• Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli

  2020cites this paper
• Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System

  2020cites this paper
• Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche

  2020cites this paper
• The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.

  2020cites this paper
• Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche

  2020cites this paper
• Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes

  2020cites this paper
• Hyperspectral and multispectral imaging in digital and computational pathology: a systematic review [Invited].

  2020cites this paper
• The Role of Innate Immunity in the Pathogenesis of Breast Cancer

  2020cites this paper
• Indicators of a pro-tumor immune response are evident at early stages of breast cancer

  2020cites this paper
• Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent

  2020cites this paper
• Hyperspectral Imaging for the Detection of Glioblastoma Tumor Cells in H&E Slides Using Convolutional Neural Networks

  2020cites this paper
• Immune microenvironment in different molecular subtypes of ductal breast carcinoma

  2020cites this paper
• Immune Escape during Breast Tumor Progression

  2020cites this paper
• The Immune Landscape in Women Cancers.

  2020cites this paper
• Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast

  2020cites this paper
• The prognostic significance of immune microenvironment in breast ductal carcinoma in situ

  2020cites this paper
• Tumor Microenvironment

  2020cites this paper
• Loss of myoepithelial calponin‐1 characterizes high‐risk ductal carcinoma in situ cases, which are further stratified by T cell composition

  2020cites this paper
• Ductal Carcinoma In Situ—Pathological Considerations

  2020cites this paper
• Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence

  2020cites this paper
• The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment

  2020cites this paper
• Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer

  2019cites this paper
• Higher densities of tumour‐infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast

  2019influential citation
• Unmasking the immune microecology of ductal carcinoma in situ with deep learning

  2019cites this paper
• The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting

  2019cites this paper
• The Immune Microenvironment of Breast Cancer Progression

  2019influential citation
• Ductal carcinoma in situ of breast: update 2019.

  2019cites this paper
• Ductal carcinoma in situ of the breast: immune cell composition according to subtype

  2019influential citation
• Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting.

  2019cites this paper
• Analysis of macrophages and neutrophils infiltrating murine mammary carcinoma sites within hours of tumor delivery.

  2019cites this paper
• Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS)

  2019cites this paper
• Bisphenol A promotes the invasive and metastatic potential of ductal carcinoma in situ and pro-tumorigenic polarization of macrophages.

  2019cites this paper
• Prognostic role of immune infiltrates in breast ductal carcinoma in situ

  2019cites this paper
• Cancer overdiagnosis: a biological challenge and clinical dilemma

  2019cites this paper
• Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies

  2019cites this paper
• Prognostic Significance of Tumour Infiltrating Lymphocytes in Ductal Carcinoma in Situ of the Breast

  2018influential citation
• Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence

  2018cites this paper
• Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast

  2018influential citation
• Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

  2018cites this paper
• Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

  2018cites this paper
• The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2−) subtype breast cancer by quantum-dot-based molecular imaging

  2018cites this paper
• Quantitative chromogenic immunohistochemical image analysis in cellprofiler software

  2018cites this paper
• New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms

  2018cites this paper
• Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression

  2018cites this paper
• DCIS of the breast : aspects on treatment and prognosis

  2018cites this paper
• Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer

  2018cites this paper
• Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

  2017cites this paper
• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

  2017cites this paper
• Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis

  2017cites this paper
• Evaluation of Inflammatory Cells ( Tumor Infiltrat ing Lymphocytes ) in Solid Tumors

  2017cites this paper
• Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features

  2017cites this paper
• Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ

  2017influential citation